European Journal of Biomedical and Pharmaceutical Sciences

DESIGN AND DEVELOPMENT OF SOLID LIPID NANOPARTICLES (SLNs) OF ZOLMITRIPTAN FOR THE TREATMENT OF MIGRAINE

Araben N. Patel* and Dr. B.G.Prajapati

ABSTRACT

Solid lipid nanoparticles (SLNs) of Zolmitriptan were developed by solvent diffusion evaporation method. Precirol® ATO 5 and Tween-20 were used as solid lipid and surfactant respectively. The formulation were optimized for independent variables (types of solid lipid, types and ratio of organic solvents, concentration of surfactant, temperature of secondary phase and drug: lipid ratio) in order to achieve desired particle size with maximum percent Entrapment efficiency (%EE). Prepared SLNs were characterized by Transmission Electron Microscopy (TEM) and zeta potential measurements. To achieve our goal, twenty five formulations (SLN1 to SLN25) of SLNs were prepared and optimized. Formulation SLN21 was selected as optimized formulation and was evaluated for the independent parameters. Optimized formulation showed particle size 11.73nm, zeta potential -35.82 mV, percent Entrapment efficiency (%EE) 72.58 and 99.48% of In-vitro % drug release after 16h. The drug release data suggested that the release of the drug is sustained.

Keywords: solid lipid nanoparticles, Zolmitriptan, solvent diffusion evaporation technique.